Question 1

What are the most cited papers from Seagen (Canada)?

Accepted Answer

The most cited paper from Seagen (Canada) is "Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study" (Barbara Pro, Ranjana H. Advani, Pauline Brice et al., 2012), with 1,001 citations. Next come "Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma" (785) and "Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels" (569).

Question 2

Which research topics does Seagen (Canada) publish most on?

Accepted Answer

By volume in 2022-now: HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Bladder and Urothelial Cancer Treatments and Renal cell carcinoma treatment.

Question 3

Which fields of science does Seagen (Canada) work in?

Accepted Answer

In all years, 62% of research at Seagen (Canada) is in Health Sciences, 32% in Life Sciences. Its largest fields are Medicine (55%), Biochemistry, Genetics and Molecular Biology (20%), Health Professions (7%). It does 1.9× the world's share of Health Sciences.

Question 4

Is Seagen (Canada)'s research output growing?

Accepted Answer

Output in 2022-2025 was 277% higher than in 2018-2021.